Quality assurance and safety of hippocampal avoidance prophylactic cranial irradiation in the multicenter randomized phase III trial(NCT01780675)  

作　　者：Oscar Candiff JoséBelderbos Anne Lisa Wolf Eugène Damen Paul van Haaren Wouter Crijns Sandra Hol Leen Paelinck Zdenko van Kesteren Jaap Jaspers Geert de Kerf Wouter van Elmpt Fred Ubbels Sanne Schagen Dirk de Ruysscher Michiel de Ruiter 

机构地区：[1]Department of Radiation Oncology,the Netherlands Cancer Institute,Amsterdam,the Netherlands [2]Department of Radiation Oncology,Catharina Hospital,Eindhoven,the Netherlands [3]Department of Radiation Oncology/Department of Oncology,Laboratory of Experimental Radiotherapy,KU Leuven,Belguim,the Netherlands [4]Department of Radiation Oncology,Institute Verbeeten,Tilburg,the Netherlands [5]Department of Radiation Oncology,Ghent University Hospital and Ghent University,Gent,Belgium [6]Department of Radiation Oncology,Amsterdam UMC-Location University of Amsterdam,Amsterdam,the Netherlands [7]Department of Radiation Oncology,Erasmus Mc Cancer Institute-Erasmus Mc University Medical Center,Rotterdam,the Netherlands [8]Department of Radiation Oncology,Antwerp University and Antwerp University Hospital/Iridium Netwerk,Antwerp,Belgium [9]Department of Radiation Oncology,University of Groningen-University Medical Center Groningen,Groningen,the Netherlands [10]Division of Psychosocial Research and Epidemiology,the Netherlands Cancer Institute,Amsterdam,the Netherlands [11]Radiation Oncology(Maastro),School for Oncology and Developmental Biology,Maastricht University Medical Center,Maastricht,the Netherlands

出　　处：《Journal of the National Cancer Center》2023年第2期135-140,共6页癌症科学进展（英文）

摘　　要：Objective:NCT01780675,a multicenter randomized phase III trial of prophylactic cranial irradiation(PCI)versus PCI with hippocampal sparing in small cell lung cancer(SCLC)investigated neurocognitive decline and safety.As part of quality assurance,we evaluated if hippocampal avoidance(HA)-PCI was performed according to the NCT01780675 trial protocol instructions,and performed a safety analysis to study the incidence and location of brain metastases for patients treated with HA-PCI.Methods:This retrospective analysis evaluated the quality of the irradiation given in the randomized controlled trial(RCT)comparing SCLC patients receiving PCI with or without hippocampal avoidance,using intensity mod-ulated radiotherapy(IMRT)or volumetric modulated arc therapy(VMAT).The dose distribution for each patient receiving HA-PCI was retrieved and analyzed to evaluate if the treatment dose constraints were met.A ques-tionnaire was sent out to all participating sites,and data on radiotherapy technique,pre-treatment dummy runs,phantom measurements and treatment electronic portal imaging device(EPID)dosimetry were collected and analyzed.As part of the safety analysis,the follow-up magnetic resonance imaging(MRI)or computerized to-mography(CT)scans on which cranial disease progression was first diagnosed were collected and matched to the radiotherapy planning dose distribution.The matched scans were reviewed to analyze the location of the brain metastases in relation to the prescribed dose.Results:A total of 168 patients were randomized in the NCT01780675 trial in 10 centers in the Netherlands and Belgium from April 2013 until March 2018.Eighty two patients receiving HA-PCI without evidence of brain metastases were analyzed.All patients were treated with 25 Gy in 10 fractions.Dummy runs and phantom measurements were performed in all institutions prior to enrolling patients into the study.The radiotherapy(RT)plans showed a median mean bilateral hippocampal dose of 8.0 Gy,range 5.4-11.4(constraint≤8.5 Gy).In six patients(7.3%)there w

关 键 词：Hippocampus-avoidance profylactic cranial irradiation Small cell lung cancer Quality assurance NCT01780675 NEUROCOGNITION 

分 类 号：R73[医药卫生—肿瘤]